Precipio, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Ilan Danieli
- Full Time Employees
- 61
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 4 Science Park New Haven CT United States of America 06511
- IPO Date
- Jun 30, 2017
- CIK
- 0001043961
- Website
- precipiodx.com
- Similar Companies
- Business
- Precipio, Inc. Precipio, Inc. (NASDAQ: PRPO) is a healthcare biotechnology company focused on cancer diagnostics that develops, manufactures, and sells proprietary diagnostic products, reagents, and services to improve diagnostic accuracy and efficiency, particularly in hematopathology for blood cancers. The company offers HemeScreen, a suite of molecular genetic diagnostic panels including Quantitative MPN Panel, ABL1 Resistance Panel, AML Panel, Anemia Panel, and Bloodhound MPN Panel with CALR mutation subtyping for rapid mutation detection; IV-Cell, a proprietary cytogenetics cell culture media enabling simultaneous culturing of four hematopoietic cell lineages to reduce diagnostic errors; and clinical laboratory testing services through its CLIA-certified facilities providing blood cancer diagnostics to oncologists nationwide, alongside biomarker testing and clinical project services for bio-pharma customers. Precipio, Inc. operates laboratories and R&D facilities in New Haven, Connecticut, and Omaha, Nebraska, targeting office-based oncologists, laboratories, hospitals, and pharmaceutical companies primarily in the United States with expanding international distribution. Founded as a cancer diagnostics specialist and headquartered in New Haven, Connecticut, the company generates the majority of its revenue from third-party payers and reported strong Q3 2025 financial results with over 30% revenue growth, $450,000 adjusted EBITDA, and $275,000 positive operating cash flow. Recent developments include terminating its at-the-market equity offering in September 2025 to emphasize responsible capital management, entering cashless warrant exercises in July 2025, expanding the Bloodhound MPN Panel in October 2024, signing a distribution agreement with Cardinal Health in February 2024 for HemeScreen, and achieving positive cash flow milestones in multiple 2025 quarters as it advances toward sustained profitability.
Company News
PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
Precipio Stock Gains Post Q2 Earnings, Revenue Momentum Strong
Precipio, Inc. (PRPO) Q2 2026 Earnings Call Transcript
Precipio Announces Q2-2026 Financial Results
Precipio (NASDAQ:PRPO) Stock Price Passes Below Two Hundred Day Moving Average – Should You Sell?
Precipio Announces Q2-2026 Shareholder Update Call
PRPO vs. NEO: Which Cancer Diagnostics Stock Is the Better Buy?
Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
Precipio to Present at the Planet MicroCap Las Vegas
Precipio Stock Slips Post Q1 Earnings Despite Revenue Growth
Precipio, Inc. (PRPO) Q1 2026 Earnings Call Transcript
Precipio Announces Q1 2026 Financial Results
Management team's 2025 market-based Options have vested
Management team’s 2025 market-based Options have vested
The Zacks Analyst Blog NVIDIA, Mastercard, AbbVie, Waterstone and Precipio
Precipio Announces Q1-2026 Shareholder Update Call
Precipio Announces Q1-2026 Shareholder Update Call
Precipio, Inc. (PRPO) Q4 2025 Earnings Call Prepared Remarks Transcript
Head to Head Analysis: Precipio (NASDAQ:PRPO) & Healthcare Triangle (NASDAQ:HCTI)
Precipio Announces Q4 and year-end 2025 Shareholder Update Call